BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $408,991,816 | -7.8% | 10,836,563 | +11.3% | 0.13% | -3.6% |
| Q2 2023 | $443,670,478 | +109.8% | 9,737,776 | +86.8% | 0.14% | +101.4% |
| Q1 2023 | $211,440,479 | -4.7% | 5,212,694 | +19.8% | 0.07% | -9.2% |
| Q4 2022 | $221,829,000 | -42.0% | 4,351,889 | -38.8% | 0.08% | -46.1% |
| Q3 2022 | $382,402,000 | -8.8% | 7,105,829 | +8.8% | 0.14% | -3.4% |
| Q2 2022 | $419,159,000 | -14.9% | 6,530,818 | +2.4% | 0.15% | +0.7% |
| Q1 2022 | $492,546,000 | -19.0% | 6,376,114 | -10.2% | 0.14% | -13.7% |
| Q4 2021 | $608,167,000 | +22.6% | 7,097,232 | +15.1% | 0.17% | +6.3% |
| Q3 2021 | $495,927,000 | +30.4% | 6,164,100 | +30.4% | 0.16% | +33.9% |
| Q2 2021 | $380,432,000 | -40.9% | 4,725,699 | -38.2% | 0.12% | -44.9% |
| Q1 2021 | $643,549,000 | -5.6% | 7,640,686 | -10.1% | 0.21% | -11.6% |
| Q4 2020 | $682,058,000 | -1.9% | 8,502,085 | -1.7% | 0.24% | -14.5% |
| Q3 2020 | $695,423,000 | +7.4% | 8,647,450 | +14.9% | 0.28% | +2.2% |
| Q2 2020 | $647,670,000 | -13.6% | 7,523,036 | -18.6% | 0.28% | -29.7% |
| Q1 2020 | $749,790,000 | -13.9% | 9,238,614 | -11.3% | 0.39% | +8.8% |
| Q4 2019 | $871,142,000 | -21.8% | 10,420,457 | -18.2% | 0.36% | -27.5% |
| Q3 2019 | $1,113,540,000 | +6.5% | 12,731,727 | -0.3% | 0.50% | +6.6% |
| Q2 2019 | $1,045,670,000 | -8.9% | 12,767,472 | -9.5% | 0.47% | -11.4% |
| Q1 2019 | $1,147,682,000 | +60.2% | 14,113,905 | +29.7% | 0.53% | +47.5% |
| Q4 2018 | $716,437,000 | +11.3% | 10,884,669 | +30.6% | 0.36% | +59.1% |
| Q3 2018 | $643,815,000 | +4.7% | 8,334,850 | +0.1% | 0.22% | -17.3% |
| Q2 2018 | $615,104,000 | +13.6% | 8,330,332 | +0.1% | 0.27% | +11.0% |
| Q1 2018 | $541,381,000 | +2.1% | 8,323,482 | +1.5% | 0.24% | +1.2% |
| Q4 2017 | $530,362,000 | +3.1% | 8,204,143 | +0.1% | 0.24% | -1.2% |
| Q3 2017 | $514,231,000 | +1.3% | 8,195,089 | -2.2% | 0.24% | -3.5% |
| Q2 2017 | $507,455,000 | +14.4% | 8,381,519 | -2.0% | 0.25% | +10.9% |
| Q1 2017 | $443,539,000 | +18.2% | 8,552,232 | +1.0% | 0.23% | +11.7% |
| Q4 2016 | $375,301,000 | +95.5% | 8,464,073 | +109.9% | 0.20% | +89.8% |
| Q3 2016 | $191,946,000 | +97.7% | 4,032,342 | +88.0% | 0.11% | +89.5% |
| Q2 2016 | $97,113,000 | +9.8% | 2,145,227 | -0.3% | 0.06% | +7.5% |
| Q1 2016 | $88,443,000 | +20.2% | 2,151,882 | +11.6% | 0.05% | +23.3% |
| Q4 2015 | $73,561,000 | +48.1% | 1,928,054 | +27.5% | 0.04% | +38.7% |
| Q3 2015 | $49,669,000 | -77.3% | 1,512,182 | -51.6% | 0.03% | -75.0% |
| Q2 2015 | $218,376,000 | -8.9% | 3,122,214 | -10.7% | 0.12% | -10.1% |
| Q1 2015 | $239,588,000 | +21.6% | 3,497,189 | +30.1% | 0.14% | +20.0% |
| Q4 2014 | $197,054,000 | +35.3% | 2,688,137 | +32.5% | 0.12% | +30.7% |
| Q3 2014 | $145,660,000 | -0.5% | 2,028,969 | +0.2% | 0.09% | +2.3% |
| Q2 2014 | $146,465,000 | -13.2% | 2,025,237 | -11.7% | 0.09% | -14.9% |
| Q1 2014 | $168,832,000 | -12.2% | 2,294,001 | -17.0% | 0.10% | -13.7% |
| Q4 2013 | $192,364,000 | -30.8% | 2,765,325 | -34.7% | 0.12% | -35.7% |
| Q3 2013 | $278,124,000 | +15.6% | 4,233,345 | +21.9% | 0.18% | +9.0% |
| Q2 2013 | $240,624,000 | – | 3,473,159 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |